Alnylam Pharmaceuticals is once again partnering with the Foundation For Rare Diseases to award a €20,000 grant to an innovative research project in the field of rare diseases using RNA interference technology.
The prize will be awarded to an innovative research project in the field of rare diseases, focusing on one of the following themes
Translational research developing an RNA interference approach and using an animal or cellular model.
Innovative vectorization of RNA interference targeting an organ or tissue.
The prize will be awarded to a senior researcher, scientific leader of a team attached to a French research organization, whose research has contributed to major advances in the field of rare diseases.
Submission of the application before March 30, 2023, 5:00 pm (Paris time).